Partnership deals are in vogueEndocyte - quoted by Sujan at Seeking Alpha as similar in market size as MCNA (back when Bioniche thought the market was $200mm) got 120mm up front from Merck, 800mm in (potential) milestones and a 50/50 split for the US market for the phase III Vintofolide." Mind you it was for more that one application... but still very nice. A deal half that size would work for me. I read that most pharmas are settling more and more for partnerships instead of buyouts, as the risk is mitigated with the FDA approval contingency. I guess the same could be said for a 2 tiered structured buyout. Something's coming. We shall see. beech